Important Safety Information
Back
  • TREMFYA® (guselkumab)

    INDICATIONS

    TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

    TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity Reactions

    Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

    Infections

    TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

    Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

    Pre-Treatment Evaluation for Tuberculosis (TB)

    Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

    Immunizations

    Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

    ADVERSE REACTIONS

    Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

    The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

    Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

    cp-82625v3

    INDICATIONS
Click on the left to see the Important Safety Information

INDICATIONS

IMPORTANT SAFETY INFORMATION

Prescribing Information
Back
  • https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf
    https://www.janssenlabels.com/package-insert/product-patient-information/TREMFYA-medication-guide.pdf

Help Your Patients Start and Stay on TREMFYA®

Downloadable Forms
X
JCP
Hover on a document on the left for a quick document preview
 
 
 

Help Your Patients Start and Stay on TREMFYA®

  1. Home
  2. TREMFYA®
  3. Treatment Support

We understand that you want to get your patients the help they may need while going through treatment. That’s why we’ve put together some support resources that can help them, whether they’re just starting a new medication or they’ve been taking it for years.

Resource Guide
A comprehensive summary of support tools for your office to help patients start and stay on treatment.

TREMFYA withMe for Your Patients

TREMFYA withMe provides a range of dedicated support and resources to help make it easier for patients as they begin, and continue, their TREMFYA® treatment journey, including:

  • Prescription fulfillment
  • Cost support
  • Savings Program enrollment
  • Injection support
  • Treatment expectations

TREMFYA withMe can help to verify insurance coverage for your patients, provide reimbursement information, find financial assistance options for eligible patients, and provide ongoing support to help patients start and stay on TREMFYA®.

Share this brochure with your patients or sign them up here.

Janssen Patient Account

Your patients and their caregivers can create an online account at MyJanssenCarePath.com, where they can learn about their insurance coverage. They can also:

  • Enroll in the TREMFYA withMe Savings Program
  • Manage their Savings Program benefits
  • Find support throughout their treatment journey

Pharmacies

TREMFYA® is available from a wide range of pharmacies.

Janssen Care Coordinators can also provide:

  • Identification of pharmacies based on your patient’s insurance coverage
  • Prescription triage to pharmacy for coordination of medication delivery to your patient's home, your office, or another convenient location

If you have any questions, please call your dedicated Care Coordinator at 844-4withMe (844-494-8463), Monday–Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support is available.

Janssen Nurse Support

Even after you’ve trained your patients to give themselves an injection of TREMFYA®, they may still have questions. For patients not enrolled in TREMFYA withMe, Janssen Nurse Support* can help answer their questions about giving themselves an injection at home, preparing their injection site prior to self-injecting, and properly disposing of their used syringe.

Connect your patients with Janssen Nurse Support at 877-CarePath (877-227-3728), available Monday–Friday, 9:00 AM to 8:00 PM ET. At all other times, a nurse will typically return their call in 15 minutes.

*Janssen Nurse Support is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.

Convenient Disposal of Used Devices

Patients who've received approval to inject at home and have been properly trained can use Safe Returns® as a simple, safe, and convenient way to dispose of their used devices—at no cost to the patient. When patients sign up, they'll receive a certified Safe Returns® sustainable mail-back envelope in the mail, along with easy-to-follow mail-back instructions. To sign up for Safe Returns®, patients can call 877-CarePath (877-227-3728) or fill out the enrollment form at JanssenSafeReturns.com/register.

Internet Resources for Your Patients

There are many useful resources available online that may help your patients understand and manage their diseases and their treatment with TREMFYA®. You may find the websites listed here helpful as referrals in educating your patients about their condition.

The links provided here are for informational purposes only. No endorsement or sponsorship is implied.

TREMFYA® Patient Website

 This website contains additional information about treatment with TREMFYA®.

American Academy of Dermatology

 The American Academy of Dermatology is dedicated to providing dermatologists with the information and resources they need to serve their patients. Patients can learn more about dermatologists and the conditions they treat.

Arthritis Foundation

 The mission of the Arthritis Foundation is to improve lives through leadership in the prevention, control, and cure of arthritis and related diseases. This website includes education and online community resources for people with arthritis and their families.

Arthritis Today

 The online home of the Arthritis Foundation’s “Arthritis Today” magazine is a great source of tips and information for people living with arthritis.

CreakyJoints

 CreakyJoints provides treatment information, advice from professionals, and public forums for people living with arthritis to share their experiences.

National Psoriasis Foundation

 The National Psoriasis Foundation (NPF) is a non-profit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected.

Call a Janssen CarePath Care Coordinator at 844-4withMe (844-494-8463), Monday−Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support available.

Sign up or log in to the Provider Portal at JanssenCarePathPortal.com where you can request and review benefits investigations, enroll eligible patients in the TREMFYA withMe Savings Program, and view their Savings Program transactions.

Important Safety Information For

  • TREMFYA®

    INDICATIONS

    TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

    TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

    WARNINGS AND PRECAUTIONS

    Hypersensitivity Reactions

    Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

    Infections

    TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

    Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

    Pre-Treatment Evaluation for Tuberculosis (TB)

    Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

    Immunizations

    Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

    ADVERSE REACTIONS

    Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

    The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

    Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

    cp-82625v3

    INDICATIONS

IMPORTANT SAFETY INFORMATION

INDICATIONS
  • Minimize
  • Expand
  • Full Screen
  • Return to Website

INDICATIONS

IMPORTANT SAFETY INFORMATION